Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1872]

How effective is accelerated partial breast irradiation in patients with early...

Dr Icro Meattini - Univerity of Florence, Florence, Italy

How effective is accelerated partial breast irradiation in patients with early breast cancer? ( Dr Icro Meattini - Univerity of Florence, Florence, Italy )

Predicting disease recurrence in patients with early triple-negative breast...

Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center...

Predicting disease recurrence in patients with early triple-negative breast cancer using circulating tumour DNA ( Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )

The emerging role of immunotherapy for the treatment of early and advanced...

Dr Rita Nanda - UChicago Medicine, Chicago, USA

The emerging role of immunotherapy for the treatment of early and advanced breast cancer ( Dr Rita Nanda - UChicago Medicine, Chicago, USA )

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with...

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )

Breast cancer incidence in post-menopausal women: Long-term influence of...

Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA

Breast cancer incidence in post-menopausal women: Long-term influence of oestrogen plus progestin versus oestrogen alone ( Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA )

Could trastuzumab deruxtecan become the new standard of care for pretreated...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients? ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

Addition of S-1 to post-operative endocrine therapy for patients with hormone...

Prof Masakazu Toi - Kyoto University, Kyoto, Japan

Addition of S-1 to post-operative endocrine therapy for patients with hormone receptor-positive HER2-negative breast cancer ( Prof Masakazu Toi - Kyoto University, Kyoto, Japan )

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2...

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1 ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early...

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

Challenges of treating elderly breast cancer patients

Dr Richard Simcock - Sussex Cancer Centre, Brighton, UK

Challenges of treating elderly breast cancer patients ( Dr Richard Simcock - Sussex Cancer Centre, Brighton, UK )

Breast cancer in older adults: A multidisciplinary view

Dr Enrique Soto - National Institute of Medical Sciences, Mexico City, Mexico

Breast cancer in older adults: A multidisciplinary view ( Dr Enrique Soto - National Institute of Medical Sciences, Mexico City, Mexico )

More from ecancer